The purpose of this study is to treat persistent MRSA carriers with vitamin D supplementation during a 12 month to see if the number of MRSA positive patients can be reduced.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
60
Cholecalciferol 4000 IU/day for 12 months
Placebo (mimic of cholecalciferol) in the same amount and same time frame as Cholecalciferol for 12 months
Karolinska University Hospital
Stockholm, Huddinge, Sweden
Karolinska University Hospital
Stockholm, Solna, Sweden
MRSA
The primary endpoint is the decline of MRSA-positive patients during a 12-month period in the treatment groups (vitamin D/Placebo) based on 5 measurements with 3 months interval.
Time frame: Baseline, 3, 6, 9 and 12 months
Vitamin D levels in serum
Time frame: baseline, 3, 6, 9, 12, 18 and 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.